1231204-55-9Relevant articles and documents
Discovery of pyrazolyl propionyl cyclohexenamide derivatives as full agonists for the high affinity niacin receptor GPR109A
Ding, Fa-Xiang,Shen, Hong C.,Wilsie, Larrisa C.,Krsmanovic, Mihajlo L.,Taggart, Andrew K.,Ren, Ning,Cai, Tian-Quan,Wang, Junying,Tong, Xinchun,Holt, Tom G.,Chen, Qing,Gerard Waters,Hammond, Milton L.,Tata, James R.,Colletti, Steven L.
scheme or table, p. 3372 - 3375 (2010/08/06)
A series of pyrazolyl propionyl cyclohexenamides were discovered as full agonists for the high affinity niacin receptor GPR109A. The structure-activity relationship (SAR) studies were aimed to improve activity on GPR109A, reduce Cytochrome P450 2C8 (CYP2C
Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment
-
Page/Page column 59-60, (2009/04/24)
The present invention encompasses compounds of Formula I: as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating atherosclerosis, dyslipidemias and the like. Pharmaceutical compositions and methods of use are also included.
NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT
-
Page/Page column 32; 58-60, (2008/06/13)
The present invention encompasses compounds of Formula (I): as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating atherosclerosis, dyslipidemias and the like. Pharmaceutical compositions and methods of use are also included.
